Headlines about Kura Oncology (NASDAQ:KURA) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kura Oncology earned a coverage optimism score of 0.03 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.7595497779736 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media headlines that may have impacted Accern’s analysis:

Several equities research analysts recently issued reports on KURA shares. Zacks Investment Research lowered shares of Kura Oncology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 18th. Citigroup Inc. set a $13.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a report on Tuesday, August 8th. Leerink Swann reissued an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. ValuEngine lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Finally, Cowen and Company started coverage on shares of Kura Oncology in a report on Thursday, September 7th. They issued an “outperform” rating for the company. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $16.00.

Shares of Kura Oncology (NASDAQ:KURA) opened at $14.95 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.80 and a quick ratio of 10.79. Kura Oncology has a fifty-two week low of $4.00 and a fifty-two week high of $15.70.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. equities analysts expect that Kura Oncology will post -1.54 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-kura-oncology-kura-stock-price/1683080.html.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Insider Buying and Selling by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.